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CASE REPORT
Regional vitiligo induced by imiquimod
treatment for in-transit melanoma metastases
Elizabeth Tkachenko, BS,a,b,c Jennifer Y. Lin, MD,a,b and Rebecca I. Hartman, MD, MPHa,b
Boston and Worcester, Massachusetts
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I
miquimod is a topical immunomodulator used
for the treatment of viral warts and superficial
basal cell carcinoma and as an emerging therapy
for lentigo maligna and cutaneous melanoma metas-
tases. Vitiligo-like depigmentation has been
described as a local adverse effect of topical imiqui-
mod therapy for melanoma1 and at distant sites in
patients treated with combination topical
monobenzone-imiquimod for metastatic mela-
noma.2 We present a case in which topical imiqui-
mod resulted in both the resolution of in-transit
metastatic melanoma and the depigmentation of
local and regional skin, suggesting a regional
lymphatic effect of this localized topical treatment.
CASE REPORT
A 78-year-old man presented with approximately
100 blue-black papules localized to the scalp that
had been increasing in number. Punch biopsy found
an atypical intradermal melanocytic proliferation
with no intraepidermal component, consistent with
in-transit stage IIIC metastatic melanoma. No pri-
mary lesion was noted by the patient or on clinical
examination. Full-body positron emission tomogra-
phy/computed tomography (CT) and brainmagnetic
resonance imaging found no evidence of metastatic
disease. Imiquimod was initially chosen as a neo-
adjuvant treatment prior to surface brachytherapy
because some of the patient’s raised scalp lesions
spontaneously flattened in the weeks after his pre-
sentation, suggesting an active immune response
that could potentially be amplified. Two skin bi-
opsies of flattened blue-black macules found tu-
moral melanosis with associated lymphocytic
infiltrates and no residual melanoma. He was subse-
quently treated with topical imiquimod 5% for
8 weeks, applying 1 packet daily for 2 weeks with
an associated inflammatory response (Fig 1, A) and
then increasing to twice-daily application for the
next 6 weeks. All visible lesions were treated and
appeared to respond clinically with flattening and
reduction in dark coloration, although there were
numerous residual blue-black macules on the scalp
consistent with tumoral melanosis. Subsequent posi-
tron emission tomography/CT imaging found no
evidence of malignancy. Brachytherapy was ulti-
mately not required because of the robust response
to topical imiquimod alone.
Fourteen months after treatment completion, he
presented for routine surveillance. Scalp examina-
tion found improving blue-black macules, which
were smaller and lighter in color compared with
prior examinations (Fig 1, B). In addition, there were
new well-demarcated depigmented patches on the
scalp, neck, and head including the perioral region
(Fig 2). Wood’s light examination confirmed depig-
mentation. Full-body skin examination found no
other depigmented lesions. There was no evidence
of locoregional recurrence, and CT of the chest/
abdomen/pelvis 1 month prior showed no evidence
of metastatic disease. Three months later, however,
seizures developed secondary to a hemorrhagic
brain mass that was consistent with melanoma on
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pathology findings. He is status postesurgical resec-
tion and radiation, and currently receiving nivolu-
mab. He has not had any additional cutaneous
metastases since initial presentation.
The patient has a history of autoimmune hypo-
thyroidism that predated his melanoma diagnosis,
which is well controlled with 50 mg levothyroxine
daily. He has no family history of autoimmune
disease, vitiligo, or skin cancer.
DISCUSSION
Topical imiquimod is a toll-like receptor 7/8
agonist reported to induce localized vitiligo-like
depigmentation months after topical use for condy-
loma acuminata,3 superficial basal cell carcinoma,4
and lentigo maligna.1 Most prior reports of vitiligo-
like depigmentation with imiquimod use note depig-
mentation localized to the site of application,
although regional depigmentation has been
reported after treatment for condyloma acuminate,3
and systemic depigmentation has been reported
with combined use of topical monobenzone and
imiquimod for cutaneous melanoma metastases.2 In
the latter report of systemic depigmentation, it was
felt the monobenzone provided the systemic effect
rather than the imiquimod.2
Given this patient’s local and regional depigmen-
tation, in conjunction with resolution of his in-transit
melanoma metastases, this case likely represents a
regional, rather than a purely local, imiquimod-
induced immune response. Interestingly, imiquimod
monotherapy has been found to induce a local and a
sentinel lymph node regional immune response in
melanoma patients, which could explain this pa-
tient’s regional vitiligo.5 Importantly, vitiligo-like
depigmentation also may be seen following systemic
immunotherapy for melanoma and is associatedwith
improved survival.6
Fig 1. In-transit melanoma metastasis of the scalp. A, The patient’s scalp after 2 weeks of
imiquimod therapy, indicating the extent of cutaneous metastases and an inflammatory
response to treatment. B, The patient’s scalp 14 months after imiquimod treatment,
demonstrating interval improvement as well as residual tumoral melanosis.
Fig 2. Imiquimod-induced vitiligo. Periauricular (A) and posterior neck (B) depigmentation
representing regional vitiligo away from the site of topical imiquimod application, which was
confined to the scalp at sites of cutaneous metastases.
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Despite leading to resolution of in-transit metas-
tasis, locoregional control with imiquimod may not
provide systemic control, evidenced by the devel-
opment of brain metastasis. Indeed, prior research
suggests topical imiquimod for melanoma does not
produce a peripheral blood response.5 The reason
for this finding is unknown but may be owing to
different immunologic requirements to treat local
versus systemic disease. A murine model of meso-
thelioma has found that local imiquimod adminis-
tration induces a local immune response that
requires CD8 T cells and natural killer cells, but not
CD4 T cells, and is sufficient to retard local, but not
distant, tumor growth.7 When CD40 antibody, to
simulate CD4 T cells, was added to local imiquimod
administration, there was distal tumor growth retar-
dation and enhanced local tumor response.7
We postulate that similar to immunotherapy-
induced vitiligo, a vitiligo-like response to topical
imiquimod treatment in melanoma patients may
portend a positive locoregional prognosis given the
possibility of a regional lymphatic treatment effect,
although systemic prognosis remains unaffected.
Further studies are needed to confirm this hypothesis.
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